Calcific aortic valve disease
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
2008 ACCP Guideline Recommendations [2]
2008 ACCP Guideline Recommendations [2]
| “ |
1. In patients with isolated calcific aortic valve disease who have not had ischemic stroke or transient ischemic attack, we suggest against antithrombotic therapy. (Level of Evidence: C) 2. In patients with isolated calcific aortic valve disease who have had ischemic stroke or transient ischemic attack not attributable to another source, we suggest aspirin (50 to 100 mg/d). (Level of Evidence: C) |
” |
Guidelines Resources
Guidelines Resources
References
References
- ↑ O’Brien KD (2006). “Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more)”. Arteriosclerosis, Thrombosis, and Vascular Biology. 26 (8): 1721–8. doi:10.1161/01.ATV.0000227513.13697.ac. PMID 16709942. Retrieved 2012-04-11. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Salem DN, O’Gara PT, Madias C, Pauker SG (2008). “Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)”. Chest. 133 (6 Suppl): 593S–629S. doi:10.1378/chest.08-0724. PMID 18574274. Retrieved 2012-04-10. Unknown parameter
|month=ignored (help)
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH